Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Viral Gastroenteritis Market Size And Revenue Forecast Through 2030

The market for viral gastroenteritis has experienced robust expansion over the past few years, projecting a rise from $7.06 billion in 2025 to $7.43 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.1%. This historical growth trajectory can be linked to several key factors including heightened public health consciousness, broadened access to healthcare services, the availability of fundamental diagnostic instruments, increased reliance on oral rehydration solutions, and enhanced disease surveillance mechanisms.

The viral gastroenteritis market is poised for significant expansion, anticipating a valuation of $9.2 billion by 2030, driven by a compound annual growth rate of 5.5%. This projected increase over the forecast period is underpinned by several key factors, including heightened investment in monitoring infectious diseases, a burgeoning requirement for quick diagnostic tools usable at the point of care, broader implementation of vaccination initiatives and preventive measures, a greater emphasis on children’s health services, and a noticeable rise in the utilization of digital platforms for disease tracking. Moreover, prominent trends shaping this market include a primary focus on expedited diagnostic testing, an increasing need for therapies that offer symptomatic relief, a stronger commitment to preventing and controlling infections, a wider application of oral rehydration solutions coupled with zinc therapy, and more sophisticated methods for observing viral outbreaks.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12127&type=smp

Viral Gastroenteritis Market Growth Drivers: What Factors Are Accelerating Expansion?

The expanding incidence of gastrointestinal conditions is anticipated to be a primary driver for the viral gastroenteritis market. Gastrointestinal (GI) disorders encompass any ailment affecting the digestive tract. Therapies and diagnostic tools for viral gastroenteritis provide essential support for individuals afflicted with this condition through suitable treatments. For illustration, the Impact of IBD Report 2023, released in September 2023 by the IBD Clinical and Research Centre in Canada, highlighted that in 2023, Canada recorded 825 cases per 100,000 for inflammatory bowel disease (IBD), affecting over 320,000 people. Projections indicate an annual rise of 2.44%, suggesting that by 2035, 1.1% of the Canadian populace, equating to 470,000 individuals, will likely be diagnosed with IBD. Consequently, the rising occurrence of digestive system issues is fueling the expansion of the viral gastroenteritis market.

Viral Gastroenteritis Market Segments: Where Are The Largest Growth Opportunities?

The viral gastroenteritis market covered in this report is segmented –

1) By Drugs: Antibiotics, Antacids, Antimotility Agents, Others Drugs

2) By Diagnosis: Physical Examination, Rapid Stool Test

3) By Indication: Watery Diarrhea, Abdominal Cramps, Pain, Other Indications

4) By Type Of Virus: Norovirus, Rotavirus, Astrovirus, Enteric Adenovirus

5) By End User: Hospitals, Clinics, Pharmaceutical Companies, Diagnostic Centers, Ambulatory Care Centers, Others End Users

Subsegments:

1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Penicillins, Macrolides, Cephalosporins

2) By Antacids: Proton Pump Inhibitors (PPIs), Histamine-2 Receptor Antagonists (H2 Blockers), Magnesium-Based Antacids, Calcium-Based Antacids, Sodium Bicarbonate

3) By Antimotility Agents: Loperamide, Diphenoxylate

4) By Other Drugs: Oral Rehydration Salts (Ors), Zinc Supplements, Antiemetics

Viral Gastroenteritis Market Trends: What Is Shaping Future Industry Growth?

In the pursuit of market dominance within the viral gastroenteritis sector, leading entities are actively engaged in the innovation of novel offerings, including specialized PCR kits aimed at diagnosing gastrointestinal infectious diseases. These Polymerase Chain Reaction kits represent sophisticated molecular biology instruments utilized for both amplifying and identifying particular segments of DNA. Illustratively, in the month of March in 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a firm headquartered in China and specializing in molecular diagnostic solutions, introduced a suite of 10 Real-Time PCR Kits engineered for the precise identification of gastrointestinal pathogens, thereby creating an all-encompassing Total PCR Solution through the synergy of their extraction solution and PCR system. This advanced Real-Time PCR Kit range encompasses the identification of a spectrum of bacterial, viral, and parasitic causative agents linked to gastrointestinal ailments. Specifically, these kits target infections stemming from diverse bacterial culprits such as Campylobacter, Salmonella, Shigella, and Clostridioides difficile, alongside viral entities including Adenovirus, Rotavirus, Astrovirus, and Norovirus. This groundbreaking development offers an optimized workflow, extending seamlessly from the initial preparation of samples through to the analysis of PCR amplification.

Viral Gastroenteritis Market Major Participants And Competitive Dynamics

Major companies operating in the viral gastroenteritis market are Pfizer Inc., Sanofi S A, Abbott Laboratories, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Mylan N V, Dr Reddys Laboratories Ltd, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd, ANI Pharmaceuticals Inc, Merck Sharp & Dohme Corp, Abbvie Inc, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Roche Holding AG, BristolMyersSquibb Company, Amgen Inc, Eli Lilly and Company, Novartis AG, Johnson and Johnson, Moderna Inc, Bharat Biotech International Ltd

Access The Complete Viral Gastroenteritis Market Report:

https://www.thebusinessresearchcompany.com/report/viral-gastroenteritis-global-market-report

Viral Gastroenteritis Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the viral gastroenteritis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral gastroenteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model